Paper28297622
Clinical Trials in the Genomic Era.
Joffe E and 2 others. J Clin Oncol, 2017. Cited by 12 papers, by iCite.
Cite this record
ConductScience Library. Clinical Trials in the Genomic Era. Papers, record 28297622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28297622
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics5
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Clinical Trials as Topic | Major topic |
| Genomics | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Molecular Targeted Therapy |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30 CA008748 | NCI NIH HHS | United States | P30CA008748 | PubMed and NIH |
Source NIH RePORTER
References60
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 22375970 | JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22375970 | PubMed |
| 2 | 27083333 | Longitudinal adverse event assessment in oncology clinical trials: the Toxicity over Time (ToxT) analysis of Alliance trials NCCTG N9741 and 979254. | Lancet Oncol | 2016 | https://conductscience.org/library/papers/27083333 | PubMed |
| 3 | 21639808 | Improved survival with vemurafenib in melanoma with BRAF V600E mutation. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21639808 | PubMed |
| 4 | 26466571 | Mutations driving CLL and their evolution in progression and relapse. | Nature | 2015 | https://conductscience.org/library/papers/26466571 | PubMed |
| 5 | 26287849 | Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. | N Engl J Med | 2015 | https://conductscience.org/library/papers/26287849 | PubMed |
| 6 | 27214515 | Genomic Alteration-Driven Clinical Trial Designs in Oncology. | Ann Intern Med | 2016 | https://conductscience.org/library/papers/27214515 | PubMed |
| 7 | 26941398 | BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. | Blood | 2016 | https://conductscience.org/library/papers/26941398 | PubMed |
| 8 | 26282654 | Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26282654 | PubMed |
| 9 | 24030381 | Clinical and biological implications of driver mutations in myelodysplastic syndromes. | Blood | 2013 | https://conductscience.org/library/papers/24030381 | PubMed |
| 10 | 27893325 | Basket Trials in Oncology: A Trade-Off Between Complexity and Efficiency. | J Clin Oncol | 2017 | https://conductscience.org/library/papers/27893325 | PubMed |
| 11 | 25805592 | Novel targeted therapies in diffuse large B-cell lymphoma. | Semin Hematol | 2015 | https://conductscience.org/library/papers/25805592 | PubMed |
| 12 | 21931113 | Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. | Blood | 2011 | https://conductscience.org/library/papers/21931113 | PubMed |
| 13 | 25810246 | The Signature Program: Bringing the Protocol to the Patient. | Clin Pharmacol Ther | 2015 | https://conductscience.org/library/papers/25810246 | PubMed |
| 14 | 25726955 | Management of adverse events associated with idelalisib treatment: expert panel opinion. | Leuk Lymphoma | 2015 | https://conductscience.org/library/papers/25726955 | PubMed |
| 15 | 26342236 | Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. | Lancet Oncol | 2015 | https://conductscience.org/library/papers/26342236 | PubMed |
| 16 | 23144193 | Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. | Haematologica | 2013 | https://conductscience.org/library/papers/23144193 | PubMed |
| 17 | 22258401 | Quantification of subclonal distributions of recurrent genomic aberrations in paired pre-treatment and relapse samples from patients with B-cell chronic lymphocytic leukemia. | Leukemia | 2012 | https://conductscience.org/library/papers/22258401 | PubMed |
| 18 | 24615778 | A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). | Blood | 2014 | https://conductscience.org/library/papers/24615778 | PubMed |
| 19 | 27197177 | Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. | Cancer Res | 2016 | https://conductscience.org/library/papers/27197177 | PubMed |
| 20 | 27167109 | A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. | Oncotarget | 2016 | https://conductscience.org/library/papers/27167109 | PubMed |
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 12 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40873988 | Scanning the horizon of personalized prevention research: an overview of ongoing European funded initiatives. | Front Public Health | 2025 | https://conductscience.org/library/papers/40873988 | PubMed |
| 40156702 | The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines. | Curr Oncol Rep | 2025 | https://conductscience.org/library/papers/40156702 | PubMed |
| 38357305 | From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38357305 | PubMed |
| 36929083 | Pharmacogenomic and Statistical Analysis. | Methods Mol Biol | 2023 | https://conductscience.org/library/papers/36929083 | PubMed |
| 34197637 | Emulating Control Arms for Cancer Clinical Trials Using External Cohorts Created From Electronic Health Record-Derived Real-World Data. | Clin Pharmacol Ther | 2022 | https://conductscience.org/library/papers/34197637 | PubMed |
| 31337605 | Challenges and approaches to implementing master/basket trials in oncology. | Blood Adv | 2019 | https://conductscience.org/library/papers/31337605 | PubMed |
| 29895903 | Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. | Blood Cancer J | 2018 | https://conductscience.org/library/papers/29895903 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28297622
GET https://conductscience.org/api/papers/v1/28297622/references?page=2